Made it to Orlando for #ACR26!!! Very excited to present my patient advocate poster tomorrow through Tuesday :) Huge thank you to @IFAiArthritis for sponsoring this research!!
Sarah Sisbot
@SarahSisbot
I'm a patient advocate who cares deeply about autoimmunity and cancer.
100 Following 27 Followers 115 Posts
Latest posts 5
I'm looking forward to #ACR26 this coming weekend!! Please check out my poster acrabstracts.org/abstract/daily… in room WB1&2 :)
acrabstracts.org Daily Step Count as a Patient-Centered Functional Endpoint in Rheumatic Disease - ACR Meeting... Background/Purpose: The American College of Rheumatology 20% response criteria (ACR20) remains one of the most widely used endpoints in rheumatoid arthritis clinical trials. However, outside of... Celebrating one year of writing (im)patient perspectives on Substack!! mrsbot.substack.com/p/happy-substa…
How well are people with #RA doing, really? I was surprised when headlines about the 10-year ARCTIC study called outcomes "excellent." Some things that stood out to me:
-The study results included multiple remission statistics which were quite different from each other (82% DAS vs 57% ACR/EULAR Boolean 2.0).
-The study didn't provide information about which malignancies and deaths were treatment related (I could only find this for the 2 year summary, where there were 5 cancers that were deemed not treatment related and 1 death that was deemed possibly treatment related).
-84% of participants were positive for anti-citrullinated peptide antibodies. This high percentage makes it harder to extrapolate these results to the general RA pool.
#rheumatoidarthritis #autoimmune #patientadvocacy
-The study results included multiple remission statistics which were quite different from each other (82% DAS vs 57% ACR/EULAR Boolean 2.0).
-The study didn't provide information about which malignancies and deaths were treatment related (I could only find this for the 2 year summary, where there were 5 cancers that were deemed not treatment related and 1 death that was deemed possibly treatment related).
-84% of participants were positive for anti-citrullinated peptide antibodies. This high percentage makes it harder to extrapolate these results to the general RA pool.
#rheumatoidarthritis #autoimmune #patientadvocacy
Thank you for this summary, Dr. Cush! It is so interesting to see the data on probiotics not being helpful in PsA. This confirms what I have personally felt after trying approximately one million probiotics (some of them quite pricey!) during the course of treating my own autoimmune disease. Happy to save my money now!
Placebo beats probiotics in PsA. And nearly 90% of well-controlled RA patients may be able to cut their targeted therapy dose in half.
Dr. Jack Cush breaks down the findings worth a closer look in this week's RheumNow podcast, Troubles with ‘Gut Feelings’.
Probiotics in PsA: 43% responded to probiotics vs. 65% on placebo. So much for the gut feeling.
RA dose reduction: Nearly 90% of patients maintained disease control after a 50% reduction in targeted therapy dosing.
TNFi safety: A study of more than 214,000 RA patients found a small but significantly increased risk of demyelinating events with TNFi.
Diagnostic bias: Women with autoimmune disease were more likely than men to have their symptoms attributed to psychiatric or psychosomatic causes.
Check out this week's podcast at buff.ly/dMa6jVX and subscribe wherever you get your podcasts.View quoted post on X
